Jacobs Journal of Cancer Science and Research

Therapeutic approach to CML in TKI era

*Timothy Allen
Department Of Oncology, Enter For Excellence In Research And Development, United States

*Corresponding Author:
Timothy Allen
Department Of Oncology, Enter For Excellence In Research And Development, United States

Published on: 2017-12-01


Chronic myeloid leukemia is a cancer that affects the cells of the bone marrow. These effected cells can grow and divide rapidly and spill into other parts of the body. It is relatively prevalent in the United States with 14% of cancer diagnoses being for CML. Immunotherapy is a new way to fight this cancer. The new era in the management of CML has started with the advent Tyrosine kinase inhibitors. This therapy stimulates one’s own immune system to fight the malignant tumor. We can classify the immunotherapeutics into TKI therapies and non TKI therapies broadly. In this paper, we discussed the causes, epidemiology, and potential immunotherapeutic techniques to treat CML.


Chronic Myeloid Leukemia; Cancer; Immunotherapy


According to the American Cancer Society, in 2014 there wereapproximately 5,980 new cases of Chronic Myeloid Leukemia (CML) diagnosed in the United States (US). In the same year, 810 deaths were also reported. This form of leukemia is highly prevalent in western countries. CML constitutes 14% of all forms of leukemia. In 2012, the age-standardized rate of incidence of CML was 1.6 per 100,000 people and in 2009, the overall five-year survival rate was 59% in the US. The five-year survival rate for CML has nearly doubled from 31%, for people diagnosed in the early 1990s, to 60% for those diagnosed between 2004 and 2010. This is mostly due to advanced targeted therapies such as Imatinib and next generation tyrosine kinase inhibitors. Moreover, survival statistics are measured in five-year intervals and may not represent all of the recent significant advances made in the treatment and diagnosis of CML. In one study of patients with CML who were consistently taking the drug Imatinib, researchers found that 90% lived at least five years.